Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) Jg. 77; H. 5; S. 505 - 520
Hauptverfasser:	Holstein, Sarah A., McCarthy, Philip L.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.04.2017 Springer Nature B.V
Schlagworte:	Angiogenesis Chemotherapy Cytotoxicity Drug development Drug dosages Drugs FDA approval Health risk assessment Humans Immunologic Factors - therapeutic use Immunomodulation Immunomodulators Internal Medicine Lenalidomide Leprosy Leukemia Malignancy Medical prognosis Medicine Medicine & Public Health Molecular modelling Molecular structure Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Patients Pharmacology/Toxicology Pharmacotherapy Review Article Stem cells Structure-function relationships Studies Thalidomide Thalidomide - analogs & derivatives Thalidomide - therapeutic use Thromboembolism Thrombosis Topical Collection on Immuno-Oncology Transcription factors Transplants & implants Ubiquitination Acute Myeloid Leukemia Bortezomib Natural Killer Cell Myeloma Thalidomide
ISSN:	0012-6667, 1179-1950, 1179-1950
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!